Should I Buy SNOA? SNOA 2026 Analysis

Should You Buy Sonoma Pharmaceuticals Inc (SNOA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

3.340

1 Day change

-1.47%

52 Week Range

6.920

Analysis Updated At

2026/01/26

Sonoma Pharmaceuticals Inc (SNOA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are bearish, there are no significant positive catalysts, and the financial performance shows declining profitability despite revenue growth. Additionally, there are no Intellectia Proprietary Trading Signals or recent news to support a strong buy decision.

Technical Analysis

The technical indicators are bearish. The MACD is below 0 and negatively contracting, the RSI is neutral at 52.532, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below the pivot level of 3.45, with key support at 3.228 and resistance at 3.672.

Options Data

Positive Catalysts

Revenue increased by 56.58% YoY in the latest quarter, indicating some growth potential.

Neutral/Negative Catalysts

Net income dropped by -12.46% YoY, EPS declined by -45.76% YoY, and gross margin slightly decreased. No recent news or significant trading trends from hedge funds or insiders. Stock trend analysis predicts a decline of -2.46% in the next day, -2.25% in the next week, and -7.95% in the next month.

Financial Performance

In Q2 2026, revenue increased to $5,604,000 (up 56.58% YoY), but net income dropped to -$534,000 (down -12.46% YoY). EPS fell to -0.32 (down -45.76% YoY), and gross margin slightly decreased to 37.83% (down -0.53% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

Analyst Rating

Wall Street analysts forecast SNOA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for SNOA is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Buy

Hold

Sell

Current: 3.390

Low

Averages

High